Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hims & Hers Health: Leaving GLP-1s Behind
10:57am, Tuesday, 03'rd Mar 2026
Hims & Hers (HIMS) remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. International expansion via the $1.15B Eucalyptus acquisition and product diversification a
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
10:40am, Tuesday, 03'rd Mar 2026
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. re
As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
10:02am, Monday, 02'nd Mar 2026
NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and diabetes studies, respectively.
Hims expansion may not come in time for risky GLP-1 business
09:16am, Monday, 02'nd Mar 2026
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soo
Global Partners LP Files 2025 Annual Report on Form 10-K
04:05pm, Friday, 27'th Feb 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that its Annual Report on Form 10-K for the year ended December 31, 202
Global Partners LP Common Units (GLP) Q4 2025 Earnings Call Transcript
12:17pm, Friday, 27'th Feb 2026
Global Partners LP Common Units (GLP) Q4 2025 Earnings Call Transcript
Global Partners Reports Fourth-Quarter and Full-Year 2025 Financial Results
08:00am, Friday, 27'th Feb 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today reported financial results for the fourth quarter and full year ended December 31
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
01:35pm, Thursday, 26'th Feb 2026
Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not be Analysis of 1,200+ patent documents reveal which programs are building durable exclusiv
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
07:00am, Thursday, 26'th Feb 2026
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anti
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%)
Hims & Hers Health: The GLP-1 Party Is Over
11:07am, Wednesday, 25'th Feb 2026
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
09:41am, Wednesday, 25'th Feb 2026
LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
12:30am, Wednesday, 25'th Feb 2026
Turning $100,000 into $1 million is a task few stocks can accomplish. Novo Nordisk doesn't seem likely to do so, especially given the challenges it is facing.
Savings Programs that offer Affordable Access to GLP-1s Available at Kroger
11:40am, Tuesday, 24'th Feb 2026
Paired with nutrition support, fresh food and easy access to dietitians, Kroger can help customers reach wellness goals CINCINNATI, Feb. 24, 2026 /PRNewswire/ -- The Kroger Co. family of companies an
